Intelligent Bio Solutions (INBS) Expected to Release Quarterly Earnings on Monday

Intelligent Bio Solutions (NASDAQ:INBS) is expected to release its Q4 2026 results before the market opens on Monday, August 17th. Analysts expect the company to post earnings of ($1.58) per share and revenue of $1.22 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:30 PM ET.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.40 by ($3.20). The firm had revenue of $1.06 million during the quarter, compared to the consensus estimate of $7.20 million. Intelligent Bio Solutions had a negative net margin of 296.73% and a negative return on equity of 176.09%. On average, analysts expect Intelligent Bio Solutions to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intelligent Bio Solutions Stock Down 7.7%

Shares of INBS stock opened at $2.77 on Friday. The firm has a market cap of $6.63 million, a price-to-earnings ratio of -0.23 and a beta of 4.21. Intelligent Bio Solutions has a 12 month low of $1.52 and a 12 month high of $24.90. The stock has a 50-day moving average price of $2.14 and a 200 day moving average price of $3.26.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Intelligent Bio Solutions stock. Alyeska Investment Group L.P. increased its position in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) by 9.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 673,492 shares of the company’s stock after acquiring an additional 59,600 shares during the quarter. Alyeska Investment Group L.P. owned about 7.12% of Intelligent Bio Solutions worth $687,000 as of its most recent SEC filing. Institutional investors own 32.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INBS. Wall Street Zen lowered shares of Intelligent Bio Solutions from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of Intelligent Bio Solutions to a “hold” rating in a report on Monday, June 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Intelligent Bio Solutions currently has a consensus rating of “Reduce”.

About Intelligent Bio Solutions

Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.